<DOC>
	<DOCNO>NCT00467779</DOCNO>
	<brief_summary>This non-randomized , open-label , study determine high safe dose cobimetinib , often take , well participant cancer tolerate cobimetinib ass pharmacokinetic effect midazolam dextromethorphan study drug .</brief_summary>
	<brief_title>Study Cobimetinib Participants With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Histologically confirm solid tumor metastatic unresectable , standard curative palliative measure exist longer effective , know therapy prolong survival Disease measurable accord Response Evaluation Criteria Solid Tumors ( RECIST ) Adequate organ marrow function Sexually active participant must use medically acceptable method contraception course study least 11 day last dose study treatment Female participant childbearing potential must negative serum pregnancy test screen No history of/or ongoing malignancy would potentially interfere interpretation pharmacodynamic efficacy assay Anticancer treatment ( e.g. , chemotherapy , radiotherapy , cytokine , hormone ) within 28 day ( 6 week nitrosoureas mitomycin C , 14 day hormonal therapy kinase inhibitor ) first dose study drug The participant recover Grade &lt; /=1 adverse event ( AEs ) within 10 % baseline value due investigational agent administer 28 day prior study enrollment The participant receive another investigational agent within 28 day first dose study drug Uncontrolled intercurrent illness include , limited , ongoing active infection , diabetes , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia The participant pregnant breastfeed The participant know positive human immunodeficiency virus ( HIV ) Allergy hypersensitivity component cobimetinib formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>